Komori
Tri Chemical Laboratories (4369) · RiskRestated

Failure to Recover Research and Development and Capital Investments

First written in FY2017. 2 of 4 entries say "Restated". Latest entry: FY2021.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017MitigatedFY2018RestatedFY2020 – FY20212017: 120172018: 120182019: 020192020: 120202021: 12021
Same theme, other companies
Non-recovery and Impairment of Research and Development Expenditure and Capital InvestmentA theme 52 companies write about · 54 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 19 of 24 companies on the "Worse" side.

11 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 52 companies compared. The sentences above are computed from all 52.
Full recordFilings, disclosures and news, newest first
  1. FY2021RestatedAnnual report

    「To prevent or diversify these risks, we are diversifying risk by focusing on marketing during the R&D phase, strengthening research and development project management, and actively pursuing partnerships with other companies.」

    In response to the risk of failing to recover R&D and capital investment, the company continues to pursue marketing during the R&D phase, project management and corporate partnerships.
  2. FY2020RestatedAnnual report

    「We are diversifying risk by focusing on marketing during the R&D phase, strengthening research and development project management, and actively pursuing partnerships with other companies.」

    In response to the risk of failing to recover R&D and capital investment, the company continues to pursue marketing during the R&D phase, project management and corporate partnerships.
  3. FY2018MitigatedAnnual report

    「To prevent or diversify these risks, we are reducing risk by focusing on marketing during the R&D phase, strengthening research and development project management, and actively pursuing partnerships with other companies.」

    The disclosure identifies marketing during the R&D phase, project management and partnerships with other companies as measures to address the risk that upfront R&D and capital expenditures may not lead to successful product development.
  4. FY2017First statedAnnual report

    「However, if product development and similar activities fail to gain traction despite substantial research and development and capital investment, this could affect our group's financial position and operating performance.」

    The disclosure describes a business model involving upfront research and development expenses and capital investment, and the potential impact if product development fails to gain traction.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Tri Chemical Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Failure to Recover Research and Development and Capital Investments | Tri Chemical Laboratories Inc. (4369) | Komori